Kousalya Selvaraj, Kuppusamy Gowthamarajan, Veera Venkata Satyanarayana Reddy Karri, Uday K Barauah, Vanka Ravisankar, Gifty M Jojo
Journal: Journal of drug targeting 2018;25(5):386-405
PMID: 28122462
Diabetic retinopathy (DR) is a leading cause of blindness in all working age groups which contribute to patient's quality of life. Considering the anatomy and physiology of barriers in the eye, the treatment and management of pathologic ocular neovascularization in the posterior segment of the eye in DR is a challenging task. The current and emerging treatment strategies are discussed in this review for better understanding and treatment of the DR. Challenges in conventional therapy and recent developments in nanocarrier based approaches (polymeric, lipid nanoparticles, liposomes and dendrimers) and their advantages in targeting ocular tissues were also discussed in this review.
Medical:
Other Literature Sources:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.